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A B S T R A C T
Background
Gastro-oesophageal reflux (GOR) is common in newborn infants. A common first line management is the use of feed thickeners.
Objectives
In newborn infants with GOR, to evaluate the use of feed thickeners in reducing signs and symptoms of GOR, acid episodes on pH
monitoring and histological evidence of oesophagitis.
Search methods
We searched MEDLINE from 1966 to March 2004, the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane
Library, Issue 2, 2004). CINAHL from 1982 to December 2001, and conference and symposia proceedings published in Pediatric
Research 1990 to 1994.We also searched conference proceedings for the European Society for PaediatricGastroenterology andNutrition
(ESPGAN) and theNorth American Society for Pediatric Gastroenterology and Nutrition (NASPGAN) from 1994 toDecember 2001.
We did not restrict the searches to the English language.
Selection criteria
All randomised controlled trials that examine the effects of thickening formulas on treating gastro-oesophageal reflux in neonates. The
eligible studies were to compare thickened feeds to no intervention (unthickened feeds).
Data collection and analysis
Two independent reviewers identified potential studies from the literature search. Quality was independently assessed by two indepen-
dent reviewers.
Main results
No studies fulfilled the requirements for inclusion in the systematic review.
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Authors’ conclusions
There is no evidence from randomised controlled trials to support or refute the efficacy of feed thickeners in newborn infants with
GOR. Given the absence of evidence, we cannot recommend using thickening agents for management of GOR in newborn infants.
P L A I N L A N G U A G E S U M M A R Y
Feed thickener for newborn infants with gastro-oesophageal reflux
There is no current evidence from randomised trials to show that adding feed thickeners to milk for newborn infants is effective in
treating gastro-oesophageal reflux. Many newborn babies (in the first four weeks of life) suffer from gastro-oesophageal reflux, especially
if they are born premature. Thickening the milk feed is a simple manoeuvre and commonly used as first line treatment for gastro-
oesophageal reflux. Thickening the feeds can be used with or without other treatments such as positioning babies on their stomach or
side, and using medications that suppress acid in the stomach or cause food to move more rapidly through the stomach. No randomised
controlled studies of sufficient quality were found in this review. Therefore, there is no current evidence to support or refute the use of
feed thickeners in treating newborn babies with gastro-oesophageal reflux.
B A C K G R O U N D
Gastro-oesophageal reflux (GOR/GERD) is a descriptive term
for the reflux of stomach contents into the oesophagus and in
mild form is a normal physiological process. It occurs more fre-
quently in neonates than in older infants and children, and is
found with higher rates in premature neonates. It is most com-
monly due to inappropriate relaxation of the lower oesophageal
sphincter (Hillemeier 1996; Sutphen 1986).
The prevalence of excessiveGOR in children is approximately 8%,
as diagnosed on 24 hour ambulatory pHmanometry studies in an
unselected healthy infant population (Sacre 1989). Symptomatic
regurgitation alone is more common and has been found to occur
in 18% of the general infant population (Boulton 1979; Chouhou
1992). pH studies are a sensitive, objective measure indicative of
acidGOR.Regurgitation alonemaynot always reflect pathological
GOR in terms of the frequency, duration and severity of reflux of
stomach contents into the oesophagus. It may be a physiological
phenomenon andwill not always be accompanied by sequelae such
as crying, screaming, irritability and/or oesophagitis.
However, at some point GOR becomes pathological. This pathol-
ogy is related to the frequency and severity of reflux episodes.
Reflux becomes pathological when it leads to insufficient caloric
intake and poor growth, oesophagitis and its sequelae (bleeding,
anaemia, stricture), or tracheal aspiration. In the older child, long
term GOR may lead to Barrett’s oesophagus (and possibly carci-
noma much later in life). The other aspect of the burden of this
condition to consider is the parental anxiety generated by a crying,
irritable child.
The clinical presentation of GOR in the neonate is variable, but
classically is with regurgitation, posseting and vomiting. Other
manifestations can include haematemesis, failure to thrive, irri-
tability, disturbed sleep, respiratory symptoms, apnoeas, recurrent
oxygen desaturation and bradycardias (Orenstein 1993). None of
these signs or symptoms are sensitive or specific for GOR. GOR
has been associated with lower respiratory tract problems in some
studies (Orenstein 1993) but not others (Kahn 1992; Jolley 1986).
The natural history of this condition is usually self limiting with
resolution during the first two years of life, correlating with devel-
opmental maturity, more upright posture with onset of walking,
and intake of more solids (Hillemeier 1981; Vanderplas 1994);
hence randomised controlled trials are essential to measure the ef-
ficacy of any treatments.
Diagnosis of this condition is still fraught with difficulties. At-
tempts at designing symptom questionnaires have been under-
taken; however, the diagnostic validity of individual symptoms is
still not proven (Orenstein 1993). The most sensitive objective
measure is the pH probe test which arbitrarily distinguishes ab-
normal from normal amounts of reflux of acidic stomach con-
tents into the oesophagus but will not detect alkaline reflux (Arasu
1980). The readings are based on the percentage of reflux time
with pH <4 (reflux index) and the frequency and duration of
reflux episodes. Normal ranges have been produced for infants
(Vandenplas 1987c). Other methods of diagnosing GOR include:
1. barium swallow - which looks only at a snapshot in time and
therefore its role is probably more to define associated anatomical
abnormalities; 2. manometry and scintigraphy - neither method
has correlated well with pH probe testing; 3. upper gastrointesti-
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nal endoscopy and oesophageal biopsy - directly looking for end
points of GOR such as inflammation; 4. radionuclide milk scans
to detect pulmonary aspiration (Hillemeier 1996).
Thickening of infant formulas has been recommended for almost
half a century for the treatment of GOR. Agents that have been
used include cereal, rice, bean gum, sodium carboxymethyl cellu-
lose, pectin and cellulose. The rationale for this therapy has been
that thickening increases the “stickiness” and weight of the feeds.
Thus, it is thought that feeds tend to be retained in the stomach
which will prevent reflux into the oesophagus (Orenstein 1987).
This assumption may be flawed and there have been studies that
show that increasing the caloric density of feeds by adding thick-
eners in fact delays gastric emptying (Minami 1984). Delayed gas-
tric emptying correlates with increased GOR (Hillemeier 1981).
In a non-randomised study, babies 6-8 weeks old with abnormal
initial pH monitoring parameters underwent thickening of their
feeds. The use of infant food thickeners was associated with a de-
crease in some of the symptoms associated with GOR including
regurgitation and improved sleep (Vanderplas 1987b). However,
the effect of thickening on respiratory symptoms does not support
a reduction in GOR. In fact, it has been shown in a crossover
study using thickened and unthickened formula in random or-
der, that thickening formulas can result in an increased number
of coughing episodes (Orenstein 1992). The physiological data
supporting a reduction in GOR with thickening of feeds are even
less convincing. Crossover pH probe studies have shown variable
effects on number of reflux episodes and oesophageal acid expo-
sure (Ramenofsky 1981; Bailey 1987). In fact, the duration of
longest acid exposure is increased (Vanderplas 1987a; Vanderplas
1987b) with thickening of feeds in non randomised controlled
studies. A subsequent prospective randomised study on infants one
to four months showed no difference in duration of longest period
pH<4, but an improvement of the reflux index (Vanderplas 1997).
Manometry studies show an increase in rate of transient lower oe-
sophageal sphincter relaxations (TLOSR), indicating worsening
GOR with thickening of formulae (Cucchiara 1995). The studies
quoted above look at the infant, not specifically at the neonatal
population.
Thickening of infant formulas is relatively free of major side ef-
fects. However, there have been anecdotal reports of acute bowel
obstruction in neonates who have received feeds thickened with
pectin and cellulose (Montagne 1974). The risk is even higher in
infantswith a premorbid predisposition to bowel obstruction, such
as cystic fibrosis or Hirschsprung disease. Some gum derivatives
have been associatedwith abdominal pain, colic anddiarrhoea sub-
sequent to fermentation in the large intestine (Vanderplas 1997).
There is also a theoretical increased risk of oesophagitis and respi-
ratory complications, based upon the finding of longer periods of
acid reflux and delayed gastric emptying with thickened formulas
(Vanderplas 1987b; Minami 1984).
Alternative treatment modalities also have potential drawbacks
and unproven efficacy. Posturing in a prone position with head
up 30 degrees has normalized pH monitoring results in only one
quarter of infants and contradicts SIDS prevention guidelines (
Vanderplas 1987a). Small frequent feeding is impractical. Low-
fat, high-carbohydrate feeds have the hypothesized advantage of
avoiding the slowingof gastric emptying associatedwith long chain
fatty acids. However, in practice they are not effective (Tolia 1992;
Vandenplas 1988; Sutphen1989). Prokinetics have significant side
effects. Cisapride is associated with prolonged QT interval on
ECG (Wysowski 1996), while metoclopramide is associated with
central nervous system and extrapyramidal side effects (Antonson
1988). Augood et al have completed a Cochrane review of use of
cisapride treatment for GOR in children. They concluded that
there was no clear evidence of reduction of symptoms of GOR
withCisapride. Therewas a significant publicationbias for positive
studies (Augood 2000). Acid suppressants do not stop reflux of
gastric contents, and antacids may be associated with the potential
for aluminum toxicity (Tsou 1991). Surgical procedures such as
fundoplication obviously have incumbent risks.
There is an obvious need for this review given the frequency of
GOR and the lack of clear evidence as to which treatments are
effective based on robust scientific evidence. As a testament to
the lack of consensus on treatment of this condition, there are
multiple therapies used to varying degrees by different clinicians
and centres around the world. As thickening of infant milk is a
simple intervention without major adverse effects, it is important
to determine its efficacy to establish whether or not it should be
considered a first line treatment for GOR.
O B J E C T I V E S
To determine if thickening of infant milk feeds reduces GOR in
newborn infants as manifested by : (a) a reduction in the signs
and symptoms of reflux; or (b) a reduced number and duration
of acid reflux episodes based on arbitrarily defined criteria on 24
hour ambulatory pH probe monitoring or by use of intraluminal
impedance; or (c) decreased oesophagitis on biopsy. Feed thick-
ening was compared against no treatment or placebo. A subgroup
analysis was planned to see if results differed for term or preterm
infants and by type of feed-thickener.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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All randomised controlled trials that examine the effects of thick-
ening formulas on treating GOR in neonates. Included studies
were to compare thickened feeds to no intervention (unthickened
feeds). Crossover studies were excluded.
Types of participants
Newborn infants with signs or symptoms suggestive of GOR,
or newborn infants with diagnosis of GOR based on 24 hour
ambulatory pH monitoring and/or oesophagitis on biopsy.
Newborn infantswere defined as full term infants less than28 days.
Preterm infants were included up to 44 weeks (postmenstrual)
corrected age. Age criteria should be fulfilled at time of initial
diagnosis.
Types of interventions
Thickeners of all types including rice, gum, or flour based, added
to all types of milk including formula and human milk, versus no
treatment or placebo.
Types of outcome measures
The outcome measures should be measured during the trial and
immediately after the intervention.
PRIMARY
1. Symptoms or signs of GOR which include regurgitation, pos-
seting, vomiting, haematemesis, failure to thrive, irritability, dis-
turbed sleep, respiratory symptoms (cough, apnoeas, and recur-
rent oxygen desaturation) and bradycardias. Each sign or symp-
tom shall be noted as a dichotomous and separate outcome. We
note that no sign or symptom is sensitive or specific for GOR.
2. Measures of gastric and oesophageal acidity based on pH mon-
itoring. pH probe study parameters to be included as quantitative
discrete variables include : (i) a reflux index (i.e. percentage of time
pH <4) , (ii) number of reflux episodes, (iii) number of episodes
lasting >5 minutes and (iv) duration of longest episode.
3. Measure of intraesophageal intraluminal electrical impedance.
Parameters to be included are discrete quantitative variables in-
cluding : (i) number of reflux episodes, (ii) height of refluxate in
the esophagus, (iii)mean GOR duration of reflux episode.
SECONDARY
3. Microscopic evidence of oesophagitis on biopsy tissue. The
definition was dichotomous based on the presence or absence of
inflammation.
4. Significant side effects of the therapy, including (i) bowel ob-
struction, (ii) diarrhoea, (iii) aspiration, (iv) cough and (v) colic.
Search methods for identification of studies
Using text word terms ’gastro-oesophageal reflux’ or ’gastro-
esophageal reflux’, or the MeSH term ’gastroesophageal reflux’,
and the MeSH term ’exp infant, newborn’, searches were made
of MEDLINE from 1966 to March 2004, the Cochrane Central
Register of Controlled Trials (CENTRAL, The Cochrane Library,
Issue 2, 2004, CINAHL from 1982 to December 2001, and con-
ference and symposia proceedings published in Pediatric Research
1990 to 1994. We also searched conference proceedings for the
European Society for Paediatric Gastroenterology and Nutrition
(ESPGAN) and the North American Society for Pediatric Gas-
troenterology and Nutrition (NASPGAN) from 1994 to Decem-
ber 2001. We did not restrict the searches to the English language.
Data collection and analysis
Criteria and methods used to assess the methodological quality
of the trials: standard method of the Cochrane Collaboration and
its Neonatal Review Group were used. The two reviewers worked
independently to search for and assess trials for inclusion and
methodological quality. Studies were assessed using the following
key criteria: blindness of randomisation, blindness of intervention,
completeness of follow up and blinding of outcome measurement.
Data was extracted independently by the reviewers. Differences
were resolved by discussion and consensus of the reviewers. If nec-
essary, investigators were contacted for additional information or
data.
For individual trials, mean differences (and 95% confidence inter-
vals) were reported for continuous variables. For categorical out-
comes the relative risk and risk difference (and 95% confidence
intervals) were reported.
For the meta-analysis, if possible, weighted mean differences (and
95% confidence intervals) were to be reported for continuous
variables, and typical estimates for relative risk and risk difference
(and 95% confidence intervals) were to be reported for categorical
outcomes. A fixed effects model was to be used.
R E S U L T S
Description of studies
See: Characteristics of excluded studies.
No suitable studies were found for inclusion in the review. On
our first search using our search strategy, 837 reports and one
conference proceeding were found, and based on their abstracts
we examined the full text reports of 15 promising publications. Of
these 15 publications, we excluded five based on the fact that they
were letters or expert opinions on the topic. We found 10 possibly
eligible studies. Of these, none of them matched our inclusion
criteria for study design or types of participants. On updating this
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review, the same criteria were implemented in March 2004 and a
further 4 possibly eligible studies were unearthed.
Gouyon 1989 was still the only study that enrolled a neonatal
population exclusively; however, it was not randomised and the
placebo group was contaminated. All of the other thirteen ex-
cluded studies, except for Vanderhoof 2003; Iacono 2002; Wenzl
2003; Bailey 1987; Vandenplas 1994 and Miller 1999 used a
study population completely outside of our defined participant age
group. These six studies used some patients within our age criteria;
however, it was not possible to analyse the neonatal group sepa-
rately. Of these six studies only Vanderhoof 2003; Iacono 2002;
Miller 1999 and Vandenplas 1994 were randomised controlled
studies. Wenzl 2003 performed a randomised, placebo-controlled
crossover study. Bailey 1987 was a crossover study which do not
appear to have been randomised.
Risk of bias in included studies
No studies met the criteria for inclusion in this review.
Effects of interventions
No studies met the criteria for inclusion in this review.
D I S C U S S I O N
Although GOR is a common condition in neonates and it is rel-
atively common practice to thicken feeds for management of this
condition, there is no evidence that it is an effective practice. Spon-
taneous resolution of GOR is related to developmental processes
and therefore occurs more frequently in neonates (especially pre-
mature neonates) than older infants and children. The neonatal
population (including premature babies) is a distinct population
in which GOR has a different prevalence, and different conse-
quences and complications compared to the older infant popula-
tion. Neonates are often at higher risk than older infants of respi-
ratory complications (including apnoeas), ventilation difficulties
and failure to thrive (given their lack of body energy reserves) -
therefore, it is not appropriate to simply generalise from infant
studies.
Nevertheless, some lessons may be learned from infant studies.
Despite the paucity of studies on the neonatal group, the infant
population has been investigated with regards to the efficacy of
thickened feeds as a treatment for gastroesophageal reflux. Van-
denplas et al studied a small group of 20 infants aged one week to
four months of age in a double-blind randomised controlled trial.
The control group underwent parental reassurance, positioning
and unthickened feeds. The study group received parental reassur-
ance, positioning and thickened formula. There was no statisti-
cally significant difference in the grade of severity of regurgitation
or pH probe parameters between control and treatment group
(Vandenplas 1994). Miller also undertook a double blind ran-
domised study of 25 general practice centres studying infants be-
tween 0 to 12 months. Ninety patients were randomised to receive
either aluminium-free alginate or placebo. The number of vomit-
ing or regurgitation episodes was significantly lower in patients re-
ceiving the alginate compared with placebo (p=0.009). The sever-
ity of vomiting showed a trend towards improvementwith alginate
but did not achieve significance (p=0.061). Subjective assessments
made by both investigators and parent/guardian of the efficacy
of alginate were favourable compared to placebo with p values of
0.008 and 0.002 respectively. On diary assessment, the improve-
ment in mean regurgitation severity and proportion of infants
with at least 10% symptom-free days achieved significance, both
with p values of 0.027. Miller concludes that the use of alginate
is an effective and safe treatment of GOR in paediatric patients
(Miller 1999). Vanderhoof et al’s study was a double blinded ran-
domised placebo controlled trial. They undertook a study which
recruited 55 babies to Enfamil AR (thickened formula) and 49 ba-
bies to a control group receiving standard commercially available
cow milk based infant formulas. The Enfamil AR group showed
symptomatic improvement at the end of the first week of the trial
with decrease percent feedings with any regurgitation (p=0.045),
total regurgitation volume score (p=0.035) and percent feeding
with choke-gag-cough (p=0.004) (Vanderhoof 2003). Iacona et al
selected patients as they consecutively presented to six paediatric
outpatient centres. They were randomised into a treatment group
comprising 82 male infants of median age 1.5 months and 84
males of the same age in the control group. The treatment group
received a formula thickened with carob flour (bean gum) which
was designed as an anti-reflux formula. They found a significant
reduction in the regurgitation score in both groups at the 4 week
and 8 week follow up consistent with the natural history of GER.
However, there was no difference in the regurgitation score be-
tween the treatment and control groups. 14 of the patients in the
treatment group stopped the thickened formula in the first 2weeks
due to diarrheoa. (Iacono 2002)
Other studies have looked at the use of thickeners in the infant
population with conflicting results, but they were not designed
as randomised controlled trials (Khoshoo 2000; Orenstein 1987;
Bailey 1987; Wenzl 2003). Wenzl studied 14 infants of mean age
42+/-32 days who had at least 5 small regurgitations or 1 large
regurgitation during a 3 day surveillance period. They were ran-
domised to receive formula A-B-A-B-A-B in this order or in reverse
order. A was thickened with 0.4% carob bean gum and B unthick-
ened formula. Video surveillance, impedence and pH probe data
show decreased mean regurgitation score (p<0.003) and decrease
GER episodes measured with impedence tracings (p<0.02) with
formula A.However, other measures from the impedence readings
were not significantly different. (Wenzl 2003) There is currently
a protocol in The Cochrane Library for a review addressing the
use of thickened feedings in children under two years of age with
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GOR (Craig 2002) which has not progressed to a published sys-
tematic review as yet.
Only one study potentially addressed the use of a thickening agent
in the neonatal population. Gouyon et al (Gouyon 1989) enrolled
neonates with GOR in a trial comparing smectite, a natural clay
whose rheological properties include increased viscosity with hy-
dration, with placebo. Smectite also has an independent mucosal
protectant effect. However, this study was not randomised, and
there was contamination of the placebo group in that some indi-
viduals in both the intervention and placebo groups were given
additional “thickeners” on the basis of undefined symptoms.
The natural history of spontaneous improvement of GOR in
neonates dictates that any treatment will seem to be efficacious in
treating GOR. Therefore, differentiating the natural history of the
disease from effect of an intervention would require comparison
with a control group, and a RCT would be essential in minimising
bias and confounding. Important outcomes need to be assessed
such as: symptoms or signs of GOR (including regurgitation, pos-
seting, vomiting, haematemesis, failure to thrive, irritability, dis-
turbed sleep, cough, apnoeas, oxygen desaturation and bradycar-
dias); gastric and oesophageal acidity based on pH monitoring;
and side effects of the therapy - bowel obstruction, diarrhoea, as-
piration, cough and colic.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
At present, there is no evidence from randomised controlled trials
to support or refute the efficacy of feed thickeners in newborn
infants with GOR. Although thickening feeds is a simple and
cheap manoeuvre, there are some theoretical side effects of this
treatment such as delayed gastric emptying with increased caloric
density of feed. Therefore, given the absence of evidence, we do
not recommend using thickening agents for management of GOR
in the neonatal population.
Implications for research
Given the lack of evidence from randomised controlled trials
(RCT) on use of thickeners in management of GOR in neonates,
we recommend that a randomised controlled study in the neonatal
population be performed.
An RCT design would be vital as GOR has a strong tendency
to resolution. Therefore, differentiating the natural history of the
disease from effect of an intervention would require comparison
with a control group. The age of the study population should
be full term infants up to four weeks and preterm infants up to
44 weeks corrected age. We recommend that the intervention of
thickening of infant feeds be compared to control, unthickened
feeds. The outcomemeasures should be symptoms of reflux disease
and pH probe study parameters. The size of the study should be
sufficient to show differences in effect and we estimate, based on
completed infant studies, that it would involve randomisation of
at least 50 patients (Miller 1999).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bailey 1987 Patients’ ages ranged from 4 days to 14 months. This was a cross over study in which each patient received both
thickened and unthickened feeds, but it does not appear to be a randomised cross over trial
Carcassonne 1975 No control group was used. The age group ranged from 40 days to five years. The patients used had anatomical
abnormalites, severe burns or brain tumours
Gouyon 1989 This study evaluated smectite in newborn infants with gastroesophageal reflux. It was rejected because of the
lack of randomisation and use of further “thickeners” in some patients in both intervention and placebo group
on the basis of undefined symptoms. Gouyon 1988 is an abbreviated report of the same study
Greally 1992 The study population was aged between 2 and 18 months. Infants were randomised to receive either cisapride
or gaviscon/carobel. There was no placebo group
Iacono 2002 The study included 166 bottle fed infants under 4 months of age. Once again this included patients who were
outside our definition of the neonatal group
Khoshoo 2000 Age range was from 4 to 10 months. Not a RCT.
Le Luyer 1992 The study group ranged in age from 2weeks to 57 months. Not a RCT (no control group). Patients were divided
into two groups using different doses of a thickener (sodium alginate) without randomisation
Miller 1999 This study was rejected on the basis of the age group encompassing 0 to 12 months. The outcome data for
newborn infants could not be separated from the data of older infants
Orenstein 1987 Ages were between 4 to 34 weeks of age. This was a cross over study, not a RCT. Each patient received both
thickened and unthickened feeds
Vandenplas 1994 Ages ranged from 1 week to 4 months old. The outcome data for newborn infants could not be separated from
the data of older infants
Vanderhoof 2003 The inclusion criteria included infants of age 14 to 120 days which was outside of the neonatal definition. The
mean was 61 days which was well outside of the neonatal age definition
Weldon 1972 Not a RCT. No control group.
Wenzl 2003 Cross over studies were excluded. The study included babies <4 months old. The mean age was 42 days which
was above the definiton of our neonates (<28 days post partum)
RCT = randomised controlled trial.
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D A T A A N D A N A L Y S E S
This review has no analyses.
WH A T ’ S N E W
Last assessed as up-to-date: 16 April 2004.
Date Event Description
21 October 2008 Amended Converted to new review format.
H I S T O R Y
Protocol first published: Issue 3, 2001
Review first published: Issue 3, 2002
Date Event Description
17 April 2004 New search has been performed This is an update of the review “Feed thickener for new-
born infants with gastro-oesophageal reflux” published in
The Cochrane Library, Issue 3, 2002 (Huang 2002).
Additional studies were searched for using the same crite-
ria and four additional studies were identified. They were
considered and included in “excluded studies”. No new
trials were identified which fulfil our criteria. Therefore,
there are no substantive changes in the review update
11 March 2002 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Rae-Chi Huang - wrote protocol, undertook literature search and critical appraisal of studies, wrote review, undertook review in 2004.
Mark Davies - instigated review, co-wrote protocol, undertook literature search and critical appraisal of studies, co-wrote review
David Forbes - gastroenterology advice, revised review
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